Veru Inc. (NASDAQ: VERU), a biopharmaceutical company in the advanced stages of clinical development, announced positive topline results from its Phase 2b QUALITY study on Monday, achieving its primary objective.
This Phase 2b study aimed to assess the effects of enobosarm compared to a placebo in patients over 60 years old who are overweight or obese and are using Wegovy for weight loss. The findings revealed that patients taking enobosarm lost, on average, 71% less lean mass and 27% more fat mass than those receiving only Wegovy.
"The promising topline results from the Phase 2b QUALITY clinical trial indicate that enobosarm treatment preserves lean mass, enhances fat loss, improves body composition changes, and prevents declines in stair climb physical function in patients treated with WEGOVY," stated Mitchell Steiner, M.D., Chairman, President, and CEO of Veru. "We intend to consult with the FDA regarding the design of the Phase 3 clinical program."
